Categories: FDA

FDA is the subject of a lot of criticism, some deserved, and some not.  However, I don't think FDA gets enough praise when it does something right.  Therefore, I thought it was important to follow up on my previous blog and let everyone know that FDA has cleared up some of the ambiguities I mentioned there.

Specifically, on December 9th, FDA issued draft guidance making it clear that federal, and not state, law determines whether a company needs to register with FDA as a wholesale distributor or 3PL as required by the DSCSA.  This clarification likely has the greatest impact on prescription drug manufacturers because the DSCSA added an exemption to the scope of activities considered to be wholesale distribution and triggering wholesale distributor licensure obligations under the DSCSA.  Under the new definition, a manufacturer distributing its own drugs is no longer considered to be engaging in wholesale distribution.

FDA should be lauded not only for providing this clarification, but for the timing of its release.  I am not sure if it was merely a coincidence, but FDA issued this draft guidance the day after the comment period for FDA's Pre-emption Guidance ended.  And by releasing it before the effective date of the reporting requirements for wholesale distributors, manufacturers have one less thing to worry about as they prepare to implement the track and trace requirements that commence on January 1, 2015.

Notwithstanding all of the good to come out of this guidance, there are still many ambiguities it does not address, such as whether states are permitted to require manufacturers to be licensed as wholesale drug distributors come January 1, 2015.  Hopefully, now that the comment period for the Pre-emption Guidance has closed, FDA will work diligently to issue final guidance and clarify this and the other remaining ambiguities.

For those entities required to report, I encourage you to review the draft guidance and evaluate whether the requirements it imposes align with the DSCSA.  FDA is accepting comments to the Draft Guidance through February 9, 2015.  For those who do not have to report, I encourage you to take advantage of the opportunity to spread a little holiday joy and submit comments thanking FDA for providing this clarification in a timely manner.

Back to Health Law Advisor Blog

Search This Blog

Blog Editors

Related Services



Jump to Page


Sign up to receive an email notification when new Health Law Advisor posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.